Literature DB >> 29215761

In vivo differentiation of common basal cell carcinoma subtypes by microvascular and structural imaging using dynamic optical coherence tomography.

Lotte Themstrup1,2, Nathalie De Carvalho3, Sabrina M Nielsen4, Jonas Olsen1,2, Silvana Ciardo3, Sandra Schuh5, Birgit M-H Nørnberg6, Julia Welzel5, Martina Ulrich7, Giovanni Pellacani3, Gregor B E Jemec1,2.   

Abstract

The subtype of basal cell carcinoma (BCC) influences the choice of treatment. Optical coherence tomography (OCT) is a non-invasive imaging tool, and a recent development of an angiographic version of OCT has extended the application of OCT to image the cutaneous microvasculature (so-called dynamic OCT, D-OCT). This study explores D-OCT's ability to differentiate the common BCC subtypes by microvascular and structural imaging. Eighty-one patients with 98 BCC lesions, consisting of three subtypes: 27 superficial BCC (sBCC), 55 nodular BCC (nBCC) and 16 infiltrative BCC (iBCC) were D-OCT scanned at three European dermatology centres. Blinded evaluations of microvascular and structural features were performed, followed by extensive statistical analysis of risk ratio (RR) and multiple correspondence analysis. nBCC lesions displayed most characteristic structural and vascular features. Serpiginous vessels, branching vessels, vessels creating a circumscribed figure and sharply demarcated hyporeflective ovoid structures in the dermis were all associated with a higher risk of the subtype being nBCC. The presence of highly present lines and dark peripheral borders at the margin of ovoid structures was negatively associated with iBCC. Lastly, the finding of hyporeflective ovoid structures protruding from epidermis correlated with sBCC. We identified various microvascular and structural D-OCT features that may aid non-invasive identification of BCC subtypes. This would allow clinicians to individualize and optimize BCC treatment as well as aid follow-up of non-surgical treatment.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  OCT angiography; biophotonics; keratinocyte carcinoma; non-invasive imaging; non-melanoma skin cancer

Mesh:

Year:  2018        PMID: 29215761     DOI: 10.1111/exd.13479

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  5 in total

Review 1.  Imaging Motion: A Comprehensive Review of Optical Coherence Tomography Angiography.

Authors:  Woo June Choi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Angulated small nests and cords: Key diagnostic histopathologic features of infiltrative basal cell carcinoma can be identified using integrated reflectance confocal microscopy-optical coherence tomography.

Authors:  Melissa Gill; Aditi Sahu; Christi Alessi-Fox; Miguel Cordova; Salvador Gonzalez; Nicusor Iftimia; Saud Aleissa; Cristian Navarrete-Dechent; Stephen Dusza; Anthony Rossi; Ashfaq A Marghoob; Milind Rajadhyaksha; Chih-Shan J Chen
Journal:  J Cutan Pathol       Date:  2020-10-12       Impact factor: 1.587

3.  1.7-Micron Optical Coherence Tomography Angiography for Characterization of Skin Lesions-A Feasibility Study.

Authors:  Yan Li; Raksha Sreeramachandra Murthy; Yirui Zhu; Fengyi Zhang; Jianing Tang; Joseph N Mehrabi; Kristen M Kelly; Zhongping Chen
Journal:  IEEE Trans Med Imaging       Date:  2021-08-31       Impact factor: 11.037

4.  Diagnostic Value of Optical Coherence Tomography Image Features for Diagnosis of Basal Cell Carcinoma.

Authors:  Fieke Adan; Klara Mosterd; Nicole W J Kelleners-Smeets; Patty J Nelemans
Journal:  Acta Derm Venereol       Date:  2021-11-30       Impact factor: 3.875

5.  Automatic skin lesion area determination of basal cell carcinoma using optical coherence tomography angiography and a skeletonization approach: Preliminary results.

Authors:  Kristen M Meiburger; Zhe Chen; Christoph Sinz; Erich Hoover; Michael Minneman; Jason Ensher; Harald Kittler; Rainer A Leitgeb; Wolfgang Drexler; Mengyang Liu
Journal:  J Biophotonics       Date:  2019-06-18       Impact factor: 3.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.